Extract from Half Yearly Report.For the second half of the...

Extract from Half Yearly Report.


For the second half of the financial year, the Company will be focused on the following activities:
• Completion of detailed analyses from the Phase 2 HIV-1 clinical trial, locking of the trial database, unblinding and statistical analyses of the data, and release of results. • Continued testing of Biotron compounds for activity against other key commercially relevant virus targets. • Aiming to execute partnership agreement(s) for the Company’s antiviral programs in worldwide markets.